Advertisement
LONDON, Nov. 9, 2017 /PRNewswire/ -- Download the full report: https://www.reportbuyer.com/product/4985942
States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the worldwide CIN market is estimated to increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Download the full report: https://www.reportbuyer.com/product/4985942
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information:Sarah SmithResearch Advisor at Reportbuyer.comEmail: [email protected]Tel: +44 208 816 85 48Website: www.reportbuyer.com
Advertisement
States, Europe (France, Germany, Italy, Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world (RoW). The Report covers the therapeutics market revenue, treatment practice and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to 2023 segmented by seven major markets. In addition, the report provides the historical and forecasted of incident cases at risk of Chemotherapy Induced Neutropenia (CIN) in 10 cancer indications till 2023.
The report covers the number of patients for 10 cancer indications (i.e., Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin's disease and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991. Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of the market size, of CIN. However, New Chemical Entities are expected to launch in the near future. According to DelveInsight, the worldwide CIN market is estimated to increase at a CAGR of 3.37% for the forecast period i.e., 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Download the full report: https://www.reportbuyer.com/product/4985942
About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com
For more information:Sarah SmithResearch Advisor at Reportbuyer.comEmail: [email protected]Tel: +44 208 816 85 48Website: www.reportbuyer.com
View original content:http://www.prnewswire.com/news-releases/chemotherapy-induced-neutropenia-cin--market-insights-epidemiology-and-market-forecast-2023-300553566.html
SOURCE ReportBuyer
